Background: Natalizumab, a highly specific alpha4-integrin antagonist, , has recently been http://t.co/yJQztim7Cg
via VAT ENGPlus Combo | VATPlus | MotionTrak http://t.co/yJQztim7Cg
via VAT ENGPlus Combo | VATPlus | MotionTrak http://t.co/yJQztim7Cg
No comments:
Post a Comment